Streetbeat News

DSKYF

Daiichi Sankyo Co., Ltd.

https://www.daiichisankyo.co.jp/

CEO

Sunao Manabe

Employees

18,434

Industry

Medicinal and Botanical Manufacturing

Open

28.63

Mkt cap

59B

Volume

100

High

31.05

P/E Ratio

36.96

52-wk high

44.64

Low

28.63

Div yield

0.01

52-wk low

25.95

Daiichi Sankyo and AstraZeneca's ENHERTU showed significant improvement in HR+, HER2 low breast cancer in the DESTINY-Breast06 trial, with plans for global regulatory submissions.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:14 am

The FDA granted accelerated approval to Enhertu, a drug developed by AstraZeneca and Daiichi Sankyo, for treating patients with unresectable or metastatic HER2 positive solid tumors who have undergone prior systemic treatment. This approval, based on objective response rate and duration of response from phase 2 trials, marks a significant milestone as the first tumor agnostic HER2-directed therapy. AstraZeneca's stock saw a slight increase following the announcement.

Portfolio Pulse from Vandana Singh

April 08, 2024 | 2:34 pm

Pfizer Inc (NYSE:PFE) is expected to report a Q4 2023 EPS loss of $(0.22) and revenues of $14.25 billion. The company's FY24 revenue forecast includes contributions from the Seagen acquisition, with adjusted EPS guidance lower than consensus. Pfizer's obesity drug trial showed efficacy but had high dropout rates due to side effects. Additionally, a former Pfizer employee was convicted of securities fraud. PFE shares dropped 1.69% in premarket trading.

Portfolio Pulse from Vandana Singh

January 25, 2024 | 2:26 pm

Merck & Company, Inc. (MRK) and Japan's Daiichi Sankyo Co. Ltd. (DSKYF) have entered into a global development and commercialization agreement for three of Daiichi Sankyo's DXd antibody-drug conjugate (ADC) candidates for multiple types of cancer. Merck will pay Daiichi Sankyo $5.5 billion in the agreement, which has a total potential consideration of up to $22 billion. Daiichi Sankyo aims for at least $6 billion of revenue from its oncology business in the fiscal year ending March 31, 2026.

Portfolio Pulse from Nabaparna Bhattacharya

October 20, 2023 | 2:59 pm

AstraZeneca and Daiichi Sankyo announced that their partnered cancer drug, datopotamab deruxtecan (Dato-DXd), met its primary goal in a phase 3 trial for breast cancer. The drug showed a significant improvement in progression-free survival compared to chemotherapy. The safety profile was consistent with previous trials, and no new safety issues were identified. The overall survival data is still being assessed. AstraZeneca's shares rose 2.66% in premarket trading following the news.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 11:46 am

AstraZeneca and Daiichi Sankyo released promising initial results from three trials related to lung cancer treatments. The TROPION-Lung04 phase 1b trial showed encouraging responses and no new safety signals for datopotamab deruxtecan in combination with durvalumab, with or without carboplatin. The FLAURA2 Phase 3 trial showed that Tagrisso in combination with chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso alone. The DESTINY-Lung02 Phase 2 trial showed that Enhertu demonstrated strong and durable tumor responses.

Portfolio Pulse from Vandana Singh

September 11, 2023 | 1:59 pm

AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan combined with Imfinzi, with or without chemotherapy, showed objective response rates of 77% and 50% and disease control rates of 92% and 93% respectively in untreated lung cancer patients. The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:29 am

The FDA has approved Daiichi Sankyo's Vanflyta for adult patients with newly diagnosed acute myeloid leukemia. This puts Daiichi Sankyo in competition with Novartis AG's Rydapt and Astellas Pharma Inc's Xospata. The approval was based on the results of the QuANTUM-First trial, which showed a 22% reduction in the risk of death compared to standard chemotherapy alone.

Portfolio Pulse from Vandana Singh

July 21, 2023 | 1:44 pm

AstraZeneca reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with advanced or metastatic non-small cell lung cancer. The drug showed a statistically significant improvement for progression-free survival compared to the current standard of care chemotherapy. However, some adverse events were observed, including some Grade 5 events (Death related to AE), which may be causing investor concern. The drug is jointly developed by AstraZeneca and Daiichi Sankyo.

Portfolio Pulse from Vandana Singh

July 03, 2023 | 9:50 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.